Michael G. Kauffman
2020
In 2020, Michael G. Kauffman earned a total compensation of $3.9M as Chief Executive Officer at Karyopharm Therapeutics, a 22% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $348,750 |
---|---|
Option Awards | $1,920,899 |
Salary | $625,624 |
Stock Awards | $1,029,886 |
Other | $11,880 |
Total | $3,937,039 |
Kauffman received $1.9M in option awards, accounting for 49% of the total pay in 2020.
Kauffman also received $348.8K in non-equity incentive plan, $625.6K in salary, $1M in stock awards and $11.9K in other compensation.
Rankings
In 2020, Michael G. Kauffman's compensation ranked 2,897th out of 13,090 executives tracked by ExecPay. In other words, Kauffman earned more than 77.9% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,897 | 78th |
Manufacturing | 1,117 | 80th |
Chemicals And Allied Products | 414 | 82nd |
Drugs | 358 | 82nd |
Pharmaceutical Preparations | 263 | 82nd |
Kauffman's colleagues
We found two more compensation records of executives who worked with Michael G. Kauffman at Karyopharm Therapeutics in 2020.
News
Karyopharm Therapeutics CEO Richard Paulson receives $8.4M in 2021
April 8, 2022
Karyopharm Therapeutics CEO Michael Kauffman's 2020 pay jumps 22% to $3.9M
April 7, 2021
Karyopharm Therapeutics CEO Michael Kauffman's 2019 pay jumps 42% to $3.2M
April 9, 2020
Karyopharm Therapeutics Executive Vice President, Chief Commercial Officer Anand Varadan receives $2.3M in 2018
April 19, 2019